CAR-T Meeting 2024 | KCAT19: an off-the-shelf cord blood-derived allogeneic CAR-T product without genome editing
Off-the-shelf allogeneic CAR T-cell products are desirable for treating patients with hematological malignancies who are not eligible for autologous CAR-T due to poor T-cell fitness and high disease burden. However, some challenges exist in their development, namely the risk of graft-versus-host disease (GvHD) due to the TCR expression on allogeneic CAR T-cells. Giulia Agliardi, PhD, University College London, London, UK, discusses a protein-based approach for generating TCR-negative CAR T-cell products from cord blood-derived T-cells without genome editing. A semi-automated closed system has been developed for the production of the KCAT19 allogeneic CAR T-cells, and the safety and efficacy of this product are being tested in patients with CD19+ relapsed/refractory (R/R) B-cell malignancies in a single-center, non-randomized, open-label Phase I trial (NCT05391490; EudraCT 2021-002878-88). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties worldwide. All rights are reserved.
